Management of Acute Lymphoblastic Leukemia in Older Patients

Seminars in Hematology

Volumn 43, Issue 2, 2006, Pages 126-133

  Larson, Richard A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ALEMTUZUMAB; AMINOPTERIN; ANTINEOPLASTIC AGENT; ASPARAGINASE; BCR ABL PROTEIN; CD52 ANTIGEN; CLOFARABINE; CORTICOSTEROID; CYTARABINE; DASATINIB; DAUNORUBICIN; FORODESINE; GRANULOCYTE COLONY STIMULATING FACTOR; HALOPERIDOL; HEMOPOIETIC GROWTH FACTOR; IMATINIB; IMMUCILLIN H; LAXATIVE; METHOTREXATE; NELARABINE; NILOTINIB; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; TRIMETREXATE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGING; ARTICLE; BIOLOGICAL ACTIVITY; BIOLOGY; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CEREBROSPINAL FLUID; CLINICAL ASSESSMENT; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONFUSION; CONSTIPATION; CYTOGENETICS; DELIRIUM; DEPRESSION; DIABETES MELLITUS; DISEASE COURSE; DISEASE EXACERBATION; DRUG BINDING; DRUG ERUPTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ELECTROLYTE DISTURBANCE; FLUID BALANCE; GROUPS BY AGE; HUMAN; HYPERGLYCEMIA; INFECTION; LIVER TOXICITY; NAUSEA AND VOMITING; PATIENT CARE; PHILADELPHIA 1 CHROMOSOME; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SIDE EFFECT; SOMNOLENCE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VIRUS ENCEPHALITIS;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; DISEASE MANAGEMENT; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 33646168564     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2006.01.007     Document Type: Article

References (50)

1. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. www.seer.cancer.gov
2. Thomas X., Olteanu N., Charrin C., Lheritier V., Magaud J.P., and Fiere D. Acute lymphoblastic leukemia in the elderly. The Edouard Herriot Hospital experience. Am J Hematol 67 (2001) 73-83
3. Göbuget N., Hoelzer D., Arnold R., Bohme A., Bartram C.R., Freund M., et al. Subtypes and treatment outcome in adult acute lymphoblastic leukemia less than or greater than 55 years. Hematol J 1 suppl 1 (2001) 186
4. Robak T., Szmigielska-Kaplon A., Wrzesien-Kus A., Wierzbowska A., Skotnicki A.B., Piatkowska-Jakubas B., et al. Acute lymphoblastic leukemia in elderly. The Polish Adult Leukemia Group experience. Ann Hematol 83 (2004) 225-231
5. Mrozek K., Heerema N.A., and Bloomfield C.D. Cytogenetics in acute leukemia. Blood Rev 18 (2004) 115-136
6. Secker-Walker L.M., Prentice H.G., Durrant J., Richards S., Hall E., Harrison G., and MRC Adult Leukaemia Working Party. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. Br J Haematol 96 (1997) 601-610
7. Groupe Francais de Cytogenetique Hematologique. Cytogenetic abnormalities in adult acute lymphoblastic leukemia. Correlations with hematologic findings and outcome. Blood 87 (1996) 3135-3142
8. Wetzler M., Dodge R.K., Mrozek K., Carroll A.J., Tantravahi R., Block A.W., et al. Prospective karyotype analysis in adult acute lymphoblastic Leukemia. The Cancer and Leukemia Group B experience. Blood 93 (1999) 3983-3993
9. Appelbaum F.R. Impact of age on the biology of acute leukemia. In: Perry M.C. (Ed). American Society of Clinical Oncology Educational Book. (2005) 528-532
10. Secker-Walker L.M., Clark R., Hawkins J.M., Maritineau M., and Moorman A.V. Age distribution of good and poor risk chromosomal subgroups among the first 1500 cases in the LRF UKCCG karyotype database in acute lymphoblastic leukemia. Br J Haematol 97 suppl 1 (1997) 45 (abstr)
11. Kantarjian H.M., O'Brien S., Smith T.L., Cortes J., Giles F.J., Beran M., et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, for adult acute lymphoblastic leukemia. J Clin Oncol 18 (2000) 547-561
12. Lewis J.H., Kilgore M.L., Goldman D.P., Trimble E.L., Kaplan R., Montello M.J., et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21 (2003) 1383-1389
13. Talarico L., Chen G., and Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration. A 7-year experience by the US Food and Drug Administration. J Clin Oncol 22 (2004) 4626-4631
14. Chessels J.M., Hall E., Prentice H.G., Durrant J., Bailey C.C., and Richards S.M. The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared. A report from the MRC Paediatric and Adult Working Parties. Leukemia 112 (1998) 463-473
15. Larson R.A., Dodge R.K., Burns C.P., Lee E.J., Stone R.M., Schulman P., et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia. Cancer and Leukemia Group B study 8811. Blood 85 (1995) 2025-2037
16. Larson R.A., Dodge R.K., Linker C.A., Stone R.M., Powell B.L., Lee E.J., et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia. CALGB study 9111. Blood 92 (1998) 1556-1564
17. Gökbuget N., de Wit M., Gerhardt A., Lipp T., Rieder H., Schwartz S., et al. Results of a shortened, dose reduced treatment protocol in elderly patients with acute lymphoblastic leukemia. Blood 96 suppl 1 (2000) 718a (abstr 3104)
18. Hoelzer D., Gökbuget N., Beck J., Burmeister T., Giagounidis A., Glasmacher A., et al. Subtype adjusted therapy improves outcome of elderly patients with acute lymphoblastic leukemia. Blood 104 suppl 1 (2004) (abstr 2732)
19. Hoelzer D., and Gökbuget N. Treatment of elderly patients with acute lymphoblastic leukemia. In: Perry M.C. (Ed). American Society of Clinical Oncology Educational Book. (2005) 533-539
20. Pagano L., Mele L., Trape G., and Leone G. The treatment of acute lymphoblastic leukaemia in the elderly. Leuk Lymph 45 (2004) 117-123
21. Pagano L., Mele L., Casorelli I., Fianchi L., Di Febo A., and Leone G. Acute lymphoblastic leukemia in the elderly. A twelve-year retrospective, single center study. Haematologica 85 (2000) 1327-1329
22. Taylor P.R.A., Reid M.M., and Proctor S.J. Acute lymphoblastic leukaemia in the elderly. Leuk Lymph 13 (1994) 373-380
23. Crome P. What's different about older people?. Toxicology 192 (2003) 49-54
24. Bressler R., and Bahl J. Principles of drug therapy for the elderly patient. Mayo Clin Proc 78 (2003) 1564-1577
25. Lipschitz D.A. Age related decline in hematopoietic reserve capacity. Semin Oncol 22 (1995) 3-5
26. Ottmann O.G., and Wassmann B. Treatment of Philadelphia chromosome positive acute lymphoblastic leukemia, in Berliner N. Hematology 2005 (2005), American Society of Hematology, Washington, DC 118-122
27. Gleissner B., Gokbughet N., Bartram C.R., et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia. A prospective study of the German Multicenter Trial Group. Blood 99 (2002) 1536-1543
28. Czuczman M.S., Dodge R.K., Stewart C.C., Frankel S.R., Davey F.R., Powell B.L., et al. Value of immunophenotyping in intensively treated adult acute lymphoblastic leukemia. Cancer and Leukemia Group B study 8364. Blood 93 (1999) 3931-3939
29. Radich J.P. Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am 15 (2001) 21-36
30. Avivi I., and Goldstone A.H. Bone marrow transplant in Ph+ ALL patients. Bone Marrow Transplant 31 (2003) 623-632
31. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344 (2001) 1038-1042
32. Ottmann O.G., Druker B.J., Sawyers C.L., Goldman J.M., Reiffers J., Silver R.T., et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100 (2002) 1965-1971
33. + ALL) treated with imatinib mesylate (Glivec). Blood 103 (2004) 1495-1498
34. Thomas D., Faderl S., Cortes J., O′Brien S., Giles F., et al. Update of the hyper-CVAD and imatinib mesylate regimen in Philadelphia (Ph) positive acute lymphocytic leukemia. Blood 104 (2004) (abstr 2738)
35. Towatari M., Yanada M., Usui N., Takeuchi J., Sugiura I., Takeuchi M., Yagasaki F., et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic. Blood 104 (2004) 3507-3535
36. Ottmann O.G., Wassmann B., Pfeifer H., Gökbuget N., Bug G., et al. Imatinib given concurrently with induction chemotherapy is superior to imatinib subsequent to induction and consolidation in newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood 104 (2004) (abstr 685)
37. Pfeifer H., Wassmann B., Hoffmann W.K., Komor M., Scheuring U., et al. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome positive acute leukemias treated with imatinib mesylate (Glivec). Clin Cancer Res 9 (2003) 4674-4681
38. Vignetti M., Fazi P., Meloni G., Chiarenza A., Malagola M., et al. Dramatic improvement in CR rate and CR duration with imatinib in adult and elderly Ph+ ALL patients. Results of the GIMEMA prospective study LAL0201. Blood 104 (2004) (abstr 2739)
39. Ottmann O.G., Wassmann B., Gökbuget N., Binckebanck A., Pfeifer H., Bruck R., et al. A randomized phase II study comparing imatinib with chemotherapy as induction therapy in elderly patients with newly diagnosed Philadelphia-positive acute lymphoid leukemias. Hematology J 5 suppl (2004) S112 (abstr)
40. Thomas D.A., Cortes J., Giles F.J., et al. The modified hyper-CVAD regimen in newly diagnosed adult acute lymphoblastic leukemia. Blood 98 suppl 1 (2001) 590a (abstr 2474)
41. Stock W., Yu D., Sanford B., Lozanski G., Cataland S., Vik R., et al. Incorporation of alemtuzumab into front-line therapy of adult acute lymphoblastic leukemia is feasible. A phase I/II study from the Cancer and leukemia Group B (CALGB 10102). Blood 106 suppl 1 (2005) 46a (abstr 145)
42. Faderl S., Gandhi V., Keating M.J., Jeha S., Plunkett W., and Kantarjian H.M. The role of clofarabine in hematologic and solid malignancies-Development of a next-generation nucleoside analog. Cancer 103 (2005) 1985-1995
43. Kurtzberg J., Ernst T.J., Keating M.J., et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol 23 (2005) 3396-3403
44. Berg S.L., Blaney S.M., Devidas M., et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies. A report from the Children's Oncology Group. J Clin Oncol 23 (2005) 3376-3382
45. DeAngelo D.J., Yu D., Dodge R.K., et al. A phase II study of 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-purine (506U78) in patients with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma. CALGB study 19801. Blood 100 suppl 1 (2003) 198a (abstr 743)
46. Isola L., Furman R.R., Gandhi V., Thomas D.A., Bennett J.C., Banita S., et al. Antileukemic activity and pharmacodynamics of intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, in phase I/II trials in patients with advanced T-cell malignancies. Blood 104 (2004) (abstr 4501)
47. Gelmon K.A., Tolcher A., Diab A.R., et al. Phase I study of liposomal vincristine. J Clin Oncol 17 (1999) 697-705
48. Thomas D.A., Sarris A., O'Brien S., et al. Phase II study of liposomal vincristine in relapsed or refractory adult acute lymphoblastic leukemia. Blood 94 suppl 1 (1999) 238b (abstr 4269)
49. Offidani M., Corvatta L., Centurioni R., Leoni F., Malerba L., Mele A., et al. High-dose daunorubicin as liposomal compound (Daunoxome) in elderly patients with acute lymphoblastic leukemia. Hematol J 4 (2003) 47-53
50. Thomas D.A., Cortes J., and Kantarjian H.M. New agents in the treatment of acute lymphoblastic leukemia. Best Pract Res Clin Haematol 15 (2003) 771-790